Pointe-Claire, Quebec – April 24, 2018 – Pharma Stulln Inc. announced today Health Canada’s approval for the first preservative free generic ophthalmic DICLOFENAC solution in Canada.
DICLOFENAC unit doses will be indicated for (i) post-operative inflammation after cataract surgery and (ii) non-chronic post-traumatic inflammation in non-penetrating wounds.
DICLOFENAC will be interchangeable to the Canadian reference.
